Search

Your search keyword '"Sutton, Kenneth"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Sutton, Kenneth" Remove constraint Author: "Sutton, Kenneth"
213 results on '"Sutton, Kenneth"'

Search Results

1. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

2. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

3. 1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

4. 1547. Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies

5. 1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women

7. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

8. Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial

9. Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

10. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

11. A Generic Clarifying Function of Philosophy of Education.

12. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

13. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study

15. Increasing Economic Stability in Fayetteville, NC Through the Creation of an Accountable Care Community to Improve the Health of Cumberland County Residents

16. INCREASING ECONOMIC STABILITY IN FAYETTEVILLE, NC, THROUGH THE CREATION OF AN ACCOUNTABLE CARE COMMUNITY TO IMPROVE THE HEALTH OF CUMBERLAND COUNTY RESIDENTS

17. INCREASING ECONOMIC STABILITY IN FAYETTEVILLE, NC, THROUGH THE CREATION OF AN ACCOUNTABLE CARE COMMUNITY TO IMPROVE THE HEALTH OF CUMBERLAND COUNTY RESIDENTS

18. LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

19. 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

20. 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

21. 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

22. Methodology for Flight Relevant Arc-Jet Testing of Flexible Thermal Protection Systems

25. Shock Layer Radiation Modeling and Uncertainty for Mars Entry

26. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

27. 2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

28. Assessment of Radiative Heating Uncertainty for Hyperbolic Earth Entry

29. Cassini/Huygens Probe Entry, Descent, and Landing (EDL) at Titan Independent Technical Assessment

30. The Influence of Ablation on Radiative Heating for Earth Entry

31. Non-Boltzmann Modeling for Air Shock-Layer Radiation at Lunar-Return Conditions

32. Radiative Heating Methodology for the Huygens Probe

33. Nonequilibrium Stagnation-Line Radiative Heating for Fire II

34. Prediction of the Aerothermodynamic Environment of the Huygens Probe

35. Preliminary Convective-Radiative Heating Environments for a Neptune Aerocapture Mission

36. Compliance with all statutory obligations etc.

37. Section 54 of the Insurance Contracts Act 1984.

38. Insurance law.

39. Inviscid Flow Computations of the Shuttle Orbiter for Mach 10 and 15 and Angle of Attack 40 to 60 Degrees

40. An Inviscid Computational Study of Three '07 Mars Lander Aeroshell Configurations Over a Mach Number Range of 2.3 to 4.5

41. Research Opportunities in Advanced Aerospace Concepts

42. The High Court widens the 'reach' of the Insurance Contracts Act.

43. Multi-Component Diffusion with Application To Computational Aerothermodynamics

44. Akai Pty Ltd v People's Insurance Co Ltd.

45. Insurance.

48. Section 3(1) of the Motor Vehicles Act 1936 (Qld.)

49. Insurance.

50. Viscous-shock-layer solutions with coupled radiation and ablation injection for earth entry

Catalog

Books, media, physical & digital resources